Back HCV Treatment

EASL 2014: MK-5172 + MK-8742 Demonstrate Good Early Post-Treatment Response Rates

A combination of 2 direct-acting antivirals, MK-5172 and MK-8742, with or without ribavirin, led to early post-treatment sustained response rates above 90% for genotype 1 hepatitis C patients, including people with cirrhosis or HIV/HCV coinfection, according to a series of presentations last week at the 49th EASL International Liver Congress in London.


Read more: